# Association of Complement C3 Inhibitor Pegcetacoplan with Photoreceptor Degeneration Beyond Areas of Geographic Atrophy

Maximilian Pfau, MD<sup>1,2,3</sup>; Steffen Schmitz-Valckenberg, MD<sup>1,2,4</sup>; Ramiro Ribeiro, MD, PhD<sup>5</sup>;
 Reza Safaei, MD<sup>5</sup>; Alex McKeown, PhD, MBA<sup>5</sup>; Monika Fleckenstein, MD<sup>2,4</sup>; Frank G. Holz,

- 6 MD<sup>1,2</sup>
- 7 1. Department of Ophthalmology, University of Bonn, Bonn, Germany
- 8 2. GRADE Reading Center, Bonn, Germany
- 9 3. Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland
- 10 4. John A. Moran Eye Center, University of Utah, Salt Lake City, USA
- 11 5. Apellis Pharmaceuticals, Waltham, Massachusetts, USA

| 12       | Running Head:     | Association of pegcetacoplan therapy with photoreceptor degeneration   |  |  |  |  |  |
|----------|-------------------|--|--|--|--|--|--|
| 13<br>14 | Keywords:         | Age-related macular degeneration, junctional zone, outer retinal degeneration, progression, optical coherence tomography |  |  |  |  |  |
| 15       | Word count:       | 3,132  |  |  |  |  |  |
| 16       | Figures:          | 3  |  |  |  |  |  |
| 17       | Tables:           | 2  |  |  |  |  |  |
| 18       | Supplementary Fig | ures: 7  |  |  |  |  |  |
| 19       | Supplementary Tal | bles: 5  |  |  |  |  |  |

#### 20 Corresponding author:

- 21 Steffen Schmitz-Valckenberg, MD
- 22 Department of Ophthalmology & Visual Sciences
- 23 John A. Moran Eye Center
- 24 University of Utah
- 25 65 North Mario Capecchi Drive
- 26 Salt Lake City, UT 84312, USA
- 27 Phone: +1 801 585 5586
- 28 Mail: <u>steffen.valckenberg@utah.edu</u>

Preservation of photoreceptors beyond areas of retinal pigment epithelium atrophy is a

critical treatment goal in eves with geographic atrophy (GA) to prevent vision loss. Thus, we

assessed the association of treatment with the complement C3 inhibitor pegcetacoplan with

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

### 29 ABSTRACT

30

31

32

33 optical coherence tomography (OCT)-based photoreceptor laminae thicknesses in this post 34 hoc analysis of the FILLY trial (NCT02503332). 35 Retinal layers in OCT were segmented using a deep-learning-based pipeline and extracted 36 along evenly spaced contour-lines surrounding areas of GA. The primary outcome measure 37 was change from baseline in (standardized) outer nuclear layer (ONL) thickness at the 5.16°-38 contour-line at month 12. 39 Participants treated with pegcetacoplan monthly had a thicker ONL along the 5.16° contour-40 line compared to the pooled sham arm (mean difference [95% CI] +0.29 z-score units [0.16, 41 0.42],P<.001). The same was evident for eyes treated with pegcetacoplan every other month 42 (+0.26 z-score units [0.13, 0.4],P<.001). Additionally, eyes treated with pegcetacoplan 43 exhibited a thicker photoreceptor inner segment layer along the 5.16°-contour-line at 44 month 12. 45 These findings suggest that pegcetacoplan could slow GA progression and lead to a lesser 46 thinning of photoreceptor layers beyond the GA boundary. Future trials in earlier disease 47 stages, i.e., intermediate AMD, aiming to slow photoreceptor degeneration warrant

48 consideration.

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 49 **INTRODUCTION**

50 Geographic atrophy (GA), the atrophic late-stage manifestation of age-related macular 51 degeneration, is a leading cause of legal blindness in industrialized countries.<sup>1–3</sup> To date, no 52 treatment options – beyond low vision aids – are available. Multiple complement inhibitors 53 are currently evaluated in clinical trials. These include pegcetacoplan (APL-2), which slowed 54 GA progression in recent Phase 2 and 3 trials.<sup>4–6</sup>

The defining lesions of GA are foci of retinal pigment epithelium (RPE), photoreceptor, and choriocapillaris atrophy that progress and fuse over time.<sup>7</sup> The area of these lesions is associated with a corresponding visual function loss,<sup>8,9</sup> impairment of activities of daily living,<sup>10</sup> and reduced quality of life.<sup>11,12</sup> Thus, the total area of RPE-atrophy has served as the primary outcome measure in multiple trials.

60 However, eyes with GA are also affected by photoreceptor degeneration beyond areas of 61 RPE-atrophy. This photoreceptor degeneration is observable as localized thinning of the outer nuclear layer (ONL) in the so-called junctional zone (500 µm band surrounding GA).<sup>13,14</sup> 62 63 In addition, photoreceptor degeneration may be more widespread, especially in association with subretinal drusenoid deposits (SDD, or reticular pseudodrusen).<sup>15–17</sup> This more diffuse 64 65 form of outer retinal degeneration can be quantified as an outer nuclear layer (ONL), 66 photoreceptor inner segment (IS), and outer segment (OS) thinning in eyes with intermediate AMD,<sup>17-19</sup> and GA.<sup>14,20-22</sup> Importantly, thinning at the level of the ONL is an established 67 surrogate of impaired light sensitivity.<sup>17-19,23</sup> A recent analysis showed that treatment with 68 69 pegcetacoplan is associated with less thinning between the inner boundary of the ellipsoid 70 zone and the outer boundary of band three. However, data on the ONL and differential data for the IS and OS layers are lacking to date.<sup>24</sup> 71

Thus, we aimed to assess the association of pegcetacoplan treatment with the change individual photoreceptor laminae thicknesses in patients with GA secondary to AMD. The presented analysis using data from the FILLY phase 2 trial (ClinicalTrials.gov identifier NCT02503332) fully accounts for the normal spatial variation in photoreceptor laminae

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

- thicknesses aiming to evaluate photoreceptor degeneration independent of the changes
- related to mere differences in RPE-atrophy progression rates.

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 78 RESULTS

- 79 Cohort
- 80 Forty-nine of the 246 clinical trial participants were excluded since they underwent spectral-
- 81 domain optical coherence tomography (SD-OCT) imaging using a Cirrus device
- 82 (Supplementary Figure S1).
- A total of 197 participants were imaged with a Heidelberg Spectralis OCT device, of whom
- 192 had follow-up imaging data available and met the prespecified modified intention-to-treat
- 85 (mITT) criteria for analysis (i.e., 97.5 % of the participants imaged with a Heidelberg
- 86 Spectralis OCT device, and 78 % of all randomized participants). The participants
- 87 (female: 122 [63.5%]; male: 70 [36.5%]) had a mean age of 79.4 years (SD: 7.53; range:
- 60.0 to 97.0) at baseline with a mean (autofluorescence based) sqrt-transformed area of
- fundus autofluorescence (FAF)-based RPE-atrophy of 2.80 mm (SD: 0.718; range: 1.59,
- 4.16). The three study arms had no distinct differences (Table 1).
- 91 Participants enrolled at clinical sites using the Cirrus device, which could not be included in
- 92 this analysis, were well-aligned with the included participants from sites using the Spectralis
- 93 device (Supplementary Table S1)

#### 94 Segmentation Accuracy

95 To assess the accuracy of the segmentation pipeline, we compared our SD-OCT-derived

96 measurement of the area of RPE-atrophy (cf., Figure 1) with the previously reported FAF-

- 97 based measurement of RPE-atrophy. For the subset of study eyes with measurable RPE-
- 98 atrophy (i.e., RPE-atrophy within the SD-OCT image frame), there was no relevant difference
- 99 (systematic bias) between the original FAF-based measurements and the SD-OCT derived
- 100 data (bias estimate [95% CI] of 0.02 mm [0.00; 0.05]. P=0.020, Supplementary Figure S2).

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 101 SD-OCT-based Trial Outcome

- 102 The primary outcome measure for the SD-OCT-based assessment mirrored the previous
- 103 FAF-based report. Specifically, for the subset of study eyes with GA within the image frame
- (n = 135), the square-root transformed atrophy progression was slower by 25% in eyes
- treated with pegcetacoplan monthly (sham pegcetacoplan monthly estimate: +0.076 mm/y,
- 106 SE: 0.038, P=0.0473), and in eyes treated with pegcetacoplan every other month (EOM)
- 107 22.2% (sham pooled pegcetacoplan EOM estimate: +0.068 mm/y, SE: 0.04, P=.09).
- 108 Photoreceptor Layer Thickness Outside of GA
- 109 At baseline, all three arms (sham pooled, pegcetacoplan monthly, and pegcetacoplan EOM)
- 110 exhibited similar degrees of photoreceptor thinning. Specifically, the ONL was thinned in the
- immediate junctional zone, with a steep gradient between 0° to 2° [approx. 0 to 582 μm] from
- the boundary of RPE-atrophy and a less steep gradient at more eccentric locations (Figure
- 113 2). Similarly, marked IS and OS thinning was evident outside of RPE-atrophy across all
- 114 groups at baseline (Supplementary Figure S3).
- 115 Change in Photoreceptor Layer Thickness Over Time
- 116 At month 12, eyes treated with pegcetacoplan exhibited a lesser degree of progressive
- thinning at the level of the ONL along their new junctional zone compared to eyes in the
- sham arm. Specifically, the ONL along the 5.16° contour-line was markedly thicker compared
- to sham in the pegcetacoplan monthly group (contrast estimate [95% CI] for pegcetacoplan
- 120 monthly sham: +0.29 z-score units [0.16, 0.42], P<.001) and in the pegcetacoplan EOM
- 121 group (pegcetacoplan EOM sham: +0.26 z-score units [0.13, 0.4], P<.001).
- 122 Likewise, the retina at the level of the IS layer was also thicker in both treatment arms
- 123 compared to sham at month 12 along the 5.16° contour-line (pegcetacoplan monthly sham:
- +0.42 z-score units [0.21, 0.62], P<.001; pegcetacoplan EOM sham: +0.34 z-score units
- 125 [0.12, 0.55], P<.001). The same was observed for the 2.58° contour-line (Table 2,
- 126 Supplementary Figure S4).

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

| 127 | At the level of the OS layer, the results were overall indistinct (Table 2). The OS layer     |
|-----|---|
| 128 | differed at month 12 only along the 2.58° contour-line markedly in thickness in the           |
| 129 | pegcetacoplan EOM group compared to sham (pegcetacoplan EOM - sham: +0.52 z-score             |
| 130 | units [0.21, 0.83], P<.001).  |
|     |   |
| 131 | Analysis of the change over time (Figure 3), revealed for the ONL and IS less thinning at the |
| 132 | level of the photoreceptors with increasing duration of treatment (i.e., estimate at month 12 |
| 133 | and 6 > month 2) and with more frequent dosing (estimates for pegcetacoplan monthly >         |
| 134 | pegcetacoplan EOM). Notably, these differences were evident through month 18. The PP          |
| 135 | analysis (Supplementary Table S2, Supplementary Figure S5) and the PP analysis excluding      |
| 136 | all visits from eyes with exudation at any time point (Supplementary Table S3,                |
|     |   |

137 Supplementary Figure S6) confirmed these results with even larger coefficients.

# 138 Association of Pegcetacoplan with Fellow Eye Photoreceptor Thickness

- 139 Fellow eye data (eyes without macular neovascularization and a baseline RPE-atrophy area
- 140  $\geq$  2.5 mm<sup>2</sup>) were available for 112 participants (eligible fellow eyes per arm: sham N=41,
- 141 pegcetacoplan monthly N=33, pegcetacoplan EOM N=38). Applying the same contour-line-
- 142 based analysis in these eyes yielded similar results concerning baseline thinning of the ONL,
- 143 IS, and OS in the junctional zone. However, there were no longitudinal changes in the fellow
- eyes of all three arms (Supplementary Table S4, Supplementary Figure S7).

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 145 **DISCUSSION**

This study analyzed the impact of the C3 inhibitor pegcetacoplan on photoreceptor
degeneration outside of RPE-atrophy using data from the randomized FILLY phase-2 trial.
Specifically, we demonstrated that eyes treated with pegcetacoplan exhibit a lesser degree
of thinning at the level of photoreceptors outside of RPE-atrophy at the end of the study

150 compared to eyes in the sham arm.

151 The area of RPE-atrophy has been established as the primary structural endpoint to quantify disease progression in eyes with GA.<sup>2</sup> For this purpose, RPE-atrophy is well suited since it 152 153 represents the boundary of deep scotomata in eyes with GA as shown by fundus-controlled perimetry studies,<sup>8,26</sup> is prognostic for reading ability,<sup>27–29</sup> as for quality of life.<sup>11,27</sup> While early 154 studies typically used fundus photography for the quantification of the area of RPE-atrophy,<sup>30</sup> 155 156 FAF-based quantification using semiautomated software such as the RegionFinder software 157 (Heidelberg Engineering, Germany) is currently the gold standard used in large-scale clinical trials<sup>31–33</sup> More recently, GA quantification with other semi and fully automated approaches 158 for FAF or OCT data has been proposed.<sup>34–37</sup> However, the area of RPE-atrophy depicts only 159 160 partially the severity of AMD in a patient with GA.

161 In the setting of intermediate AMD and GA, it is now established that photoreceptors –

162 especially in association with SDD – show degenerative changes over time in a macula-wide

163 manner.<sup>15,17,20,21,38</sup> Importantly, histopathologic data are congruent with photoreceptor

degeneration distant to the boundary of RPE-atrophy,<sup>14</sup> and suggest that rod photoreceptor

degeneration precedes cone degeneration in AMD.<sup>39,40</sup> Therefore, treatment of the non-

166 exudative component of AMD should ideally address not only RPE-atrophy but also

167 photoreceptor degeneration in the broader sense. Thus, we have analyzed the association of

168 pegcetacoplan with photoreceptor degeneration outside of RPE-atrophy.

169 Interestingly, the analyses for all three photoreceptor laminae demonstrated that

170 pegcetacoplan was associated with less thinning at the level of photoreceptors outside areas

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

| 171 | of RPE-atrophy. Considering Bradford Hill's criteria for causation, <sup>41</sup> the here observed             |
|-----|---|
| 172 | associations may be causal. First and foremost, the association strength is substantial,                        |
| 173 | follows a plausible temporal sequence (estimate increases over time), and shows a biological                    |
| 174 | gradient (dose-response relationship with a more substantial impact for eyes treated monthly                    |
| 175 | instead of EOM). Moreover, the association is specific, as evidenced by the absence of an                       |
| 176 | association in the fellow eyes. Since photoreceptor thinning correlates closely to impaired                     |
| 177 | light sensitivity, <sup>17,19,42–44</sup> it is possible that the observed changes are functionally beneficial. |
|     |   |
| 178 | Overall, the results shown here align with the previous analysis by Sophie Riedl and                            |
| 179 | coworkers. <sup>24</sup> Through differential analysis of all three photoreceptor laminae, our data             |
| 180 | suggests that their observed effect (based on a combined IS+OS layer definition) is                             |
| 181 | predominantly attributable to changes at the IS level. Importantly, our analysis fully                          |
| 182 | accounted for the spatial variation in photoreceptor laminae thickness through                                  |
| 183 | standardization. Thus, our results attest that the preservation of photoreceptor laminae                        |
| 184 | thickness in the junctional zone can not be attributed to an overall less eccentric junctional                  |
| 185 | zone in treated eyes at month 12 due to the slower RPE-atrophy progression. Instead, the                        |
| 186 | observation presents a genuine lesser degree of photoreceptor thinning independent of the                       |
| 187 | underlying RPE-atrophy progression.   |
| 188 | As a related concept, Wu and coworkers have proposed 'nascent GA', a combination of OCT                         |
| 189 | imaging signs preceding RPE-atrophy, as an endpoint applicable to evaluate retinal                              |
|     |   |

190 degeneration in eyes with intermediate AMD,<sup>45</sup> and demonstrated its prognostic value.<sup>46</sup> This

191 concept was more recently incorporated by the Classification of Atrophy Meeting (CAM)

192 consortium as a part of incomplete RPE and outer retinal atrophy (iRORA).<sup>47,48</sup> Besides

incident iRORA (or nGA) as an endpoint, the rate of iRORA to RPE-atrophy transition distant

to the junctional zone has been proposed as an endpoint.<sup>49</sup> In another post-hoc study of the

195 FILLY trial, a reduced iRORA to RPE-atrophy transition rate in eyes treated with

196 pegcetacoplan was reported.<sup>50</sup> Further studies are warranted to examine whether the

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

| 197 | observed lesser thinning at the level of the ONL along contour-lines reflects the sum of         |  |
|-----|--|--|
| 198 | decreased focal thinning primarily, <sup>50</sup> or reduced thinning in a 'macula-wide' manner. |  |

#### 199 Limitations

This analysis was a post-hoc study. Accordingly, the results must be considered hypothesis-generating rather than confirming.

202 The approach of using 'traveling' contour-lines (after standardization of the thickness data)

203 entails assumptions. This includes the absence of spatial patterns of (marked) photoreceptor

204 degeneration unrelated to the junctional zone. The relative stability (or trend toward slight

thinning) of the junctional zone photoreceptor thicknesses over time in the here presented

<sup>206</sup> fellow eye data and previous natural-history data implies that these assumptions are met.<sup>20</sup>

207 Notably, functional evidence will be needed to demonstrate genuine photoreceptor protection

with absolute certainty (instead of the unlikely case of subtle thickening due to other

209 causes).<sup>51</sup> There is no evidence that the here observed findings are a result of 'pre- or

subclinical exudation', given that the analysis excluding all visits from eyes that developed

211 exudation at any time point showed consistent results (Supplementary Table S3,

212 Supplementary Figure S6).

213 It is unclear why IS thickness showed the most distinct change in treated eyes.

214 Histopathologic data would suggest that both IS and OS thickness are suitable biomarkers

for photoreceptor integrity. In contrast, ONL thickness is partially confounded by HFL.<sup>14</sup>

216 Ultrahigh-resolution OCT technology would most likely provide more precise estimates of

217 change-over-time in IS and OS thickness given the greater axial resolution.<sup>52</sup> Last, analysis

of photoreceptor degeneration outside of RPE-atrophy in the larger phase 3 trials

219 investigating the same drug is warranted (i.e., DERBY, OAKS) and across investigational

drugs (including among other avacincaptad pegol,<sup>53</sup> IONIS-FB-LRx,<sup>54</sup> FHTR2163<sup>55</sup>).

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 221 CONCLUSION

- 222 In summary, this post-hoc analysis of the FILLY trial showed that treatment with
- 223 pegcetacoplan was associated with less outer retinal thinning over time in a dose-dependent
- 224 manner. Specifically, eyes treated with monthly pegcetacoplan (compared to controls)
- exhibited at month 12 relatively more intact tissue at the level of the ONL, IS, and OS
- 226 Iaminae outside of the RPE-atrophy junctional zone. These results may support a therapeutic
- 227 effect of pegcetacoplan on photoreceptors in eyes with GA.

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 228 METHODS

- 229 Clinical Trial Data
- 230 This post-hoc analysis was conducted between August 2021 and February 2022 and based
- 231 on data acquired previously in the FILLY trial and is reported with adherence to the
- 232 CONSORT standard. The protocol has been described previously (study start date:
- 233 September 24, 2015, primary completion date: July 14, 2017).<sup>5</sup> Ethics approval was obtained
- from all necessary boards, written informed consent was obtained from all participants, and
- 235 participants did not receive a stipend.<sup>5</sup> Sex was self-reported.
- FILLY was a multicenter, randomized, single-masked, sham-controlled study to assess the
- safety of pegcetacoplan in patients with GA secondary to AMD. Study participants had to
- have a total GA area  $\geq$  2.5 mm<sup>2</sup> (with one focus of GA  $\geq$  1.25 mm<sup>2</sup> in eyes with multifocal GA)
- and  $\leq$  17.5 mm<sup>2</sup> as assessed by fundus autofluorescence imaging. A total of 246 participants
- were included and randomized in a 2:2:1:1 manner to pegcetacoplan monthly,
- 241 pegcetacoplan every other month (EOM), sham monthly, or sham EOM.<sup>5</sup>
- 242 Study participants in the monthly group received pegcetacoplan (or sham) injections and
- study procedures monthly until month 12. Participants in the EOM groups received
- 244 pegcetacoplan (or sham) injections every two months until month 12. In addition, all
- participants were imaged at a month 15 and month 18 follow-up visit (3 and 6 months after
- the last injection, respectively).<sup>5</sup>

#### 247 Imaging Data

Besides fundus autofluorescence (FAF) imaging, participants underwent (among other imaging modalities) SD-OCT imaging, either with a Spectralis device (20°x20°, 49 B-scans, N=197 participants, Heidelberg Engineering, Heidelberg, Germany) or with a Cirrus device (N=49 participants, Carl Zeiss Meditec, Jena, Germany). The first group (i.e., participants imaged with a Spectralis device) was included in this analysis (Supplementary Figure S1). Data from five participants were excluded due to lack of follow-up or deviation from the SD-

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

254 OCT protocol. Data acquired with the Cirrus device were excluded due to the lower axial 255 resolution.

## 256 Prespecified Study Population and Pooling of the Sham Arms

In analogy to the prespecified analysis of the primary endpoint,<sup>5</sup> the modified intention-to-

treat (mITT) population included all participants with at least one injection and at least one

follow-up examination at month 2 (or later) at which efficacy data were collected. The per-

260 protocol (PP) population included all participants from the mITT population that did receive

261 no less than 75% of their expected injections before month 12 (i.e., no less than nine

[monthly group] or four injections [EOM group]) and the participants that did not receive the

263 incorrect medication throughout the study. We also report the results for the PP population,

264 excluding all visits from eyes that developed exudation at any time point. Both sham arms

<sup>265</sup> were pooled for the analyses.<sup>5</sup>

#### 266 Image Data Segmentation and Standardization

267 A previously validated convolutional neural network (CNN)<sup>20</sup> was applied to segment the

retinal layers (cf., eMethods for layer definitions and segmentation methods). For the primary

analyses, we compared photoreceptor laminae distances at fixed distances to the boundary

270 of GA across time. Since these contour-lines 'traveled' with GA progression, all OCT

- 271 thickness data were standardized to account for the normal topographic difference in
- 272 photoreceptor laminae thickness and the effect of age. Specifically, we subtracted for each
- 273 A-scan in the en-face maps the age-adjusted normal value of a given layer thickness and
- 274 divided that value by the normal location-specific standard deviation (i.e., transformation to z-

275 score units). This process has been described previously in detail.<sup>20</sup>

#### 276 Feature Extraction

- 277 The mean thickness values for the three photoreceptor laminae (ONL, IS, OS) were
- 278 extracted along evenly spaced contour-lines around the lesions of GA (width: 0.43° [126 μm

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

| 279 | in an emmetropic eye]). <sup>20</sup> The statistical analyses were performed for three representative |
|-----|--|
| 280 | contour-lines (distances to the GA boundary: 0.43°, 2.58°, and 5.16° [126 $\mu m,$ 751 $\mu m,$ and    |
| 281 | 1502 $\mu$ m in an emmetropic eye]). These evenly spaced contour-lines were derived through            |
| 282 | dilation of the initial segmentation of GA. Outer contour-lines could be discontinuous due to          |
| 283 | the image-frame. Notably, the contour-lines were defined on the current (i.e., same visit date)        |
| 284 | position of the GA boundary for all visits. This means that the counter-lines 'traveled' as the        |
| 285 | lesions expanded. The generated data are thus independent of the underlying rate of RPE-               |
| 286 | atrophy progression (i.e., not a mere representation of the slowed rate of GA progression              |
| 287 | with treatment). In the absence of treatment effects, there should be a slight thinning of             |
| 288 | photoreceptor laminae over time due to a subtle, 'macula-wide' component of photoreceptor              |
| 289 | degeneration. <sup>20</sup>  |

290 Statistical analyses

The analyses were performed in the software environment R (version 4.1.0),<sup>56</sup> using the add on libraries dplyr (version 1.0.7),<sup>57</sup> ggplot2 (version 3.3.5),<sup>58</sup> lme4 (1.1-27.1),<sup>59</sup> and emmeans (version 1.6.2-1).<sup>60</sup>

294 The primary outcome measure was the between-group difference in change from baseline of 295 the ONL thickness along the 5.16° contour-line at month 12. This distance was elected as 296 the primary outcome measure to be genuinely independent of the junctional-zone component 297 of GA. We also examined two additional contour-lines (0.43°, 2.58°, besides 5.16°), and fitted 298 for each photoreceptor layer (ONL, IS, OS), a linear mixed model (LMM) based on the 299 observed data (i.e., no imputation). The dependent variable was the change in layer 300 thickness (z-score) from baseline, and the independent variables (fixed effects) were the 301 treatment arm (pegcetacoplan monthly, pegcetacoplan EOM, and pooled sham), baseline 302 layer thickness, visit (month 2, 6, 12, 18), and the treatment arms by visit interaction. The 303 model included the patient ID as a random effect. The Kenward-Roger approximation was 304 used to estimate the denominator degrees of freedom. P-values were adjusted for the three 305 pairwise contrasts between the three groups (Tukey's single-step multiple comparison

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

| 306 | procedure). In this post-hoc analysis, estimates from a total of 27 LMMs are presented (3       |
|-----|---|
| 307 | [contour-lines] x 3 [layers: ONL, IS, OS] x 3 [analyses: mITT, PP, fellow eyes]).               |
| 308 | As an additional quality-control of the OCT segmentation, we performed an OCT-based             |
| 309 | analysis of the effect of pegcetacoplan on RPE-atrophy progression rates in analogy to the      |
| 310 | autofluorescence-based analysis in the original publication. $^{5}$ The change in square-root-  |
| 311 | transformed RPE-atrophy area from baseline was the dependent variable. The treatment arm        |
| 312 | (pegcetacoplan monthly, pegcetacoplan EOM, and pooled sham), baseline square-root-              |
| 313 | transformed RPE-atrophy area, visit (month 2, 6, 12, 18), and the treatment arms by visit       |
| 314 | interaction and the sqrt-baseline-area by visit interaction were included as the fixed effects. |
| 315 | The model included the patient ID as a random effect. In addition, a Bland-Altman analysis      |

316 was performed to compare the OCT and FAF data.<sup>61</sup>

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 317 ADDITIONAL INFORMATION

#### 318 Author Contributions

- All authors are responsible for conception and design of the study. MP, and SSV are
- 320 responsible for the analysis of the data. All authors contributed to interpretation of data,
- 321 drafting of the manuscript, critical revision of the manuscript, final approval of the manuscript.

#### 322 Competing interests

- 323 **Funding:** This study was funded by Apellis Pharmaceuticals, Waltham, Massachusetts,
- 324 USA.
- 325 Methods development relevant to this work was supported by a National Institutes of Health
- 326 Core Grant (EY014800), and an Unrestricted Grant from Research to Prevent Blindness,
- 327 New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah,
- and the German Research Foundation (DFG) grant no.: PF950/1-1 (to MP), and FL658/4-1
- 329 and FL658/4-2 (to MF).

#### 330 Financial Disclosures:

- 331 **M. Pfau** reports personal fees from Apellis and Novartis outside the submitted work.
- 332 S. Schmitz-Valckenberg reports grants from Acucela/Kubota Vision, personal fees from
- Apellis, grants and personal fees from Novartis, grants and personal fees from Allergan,
- 334 grants and personal fees from Bayer, grants and personal fees from Bioeq/Formycon, grants,
- 335 personal fees and non-financial support from Carl Zeiss MediTec AG, grants and non-
- financial support from Centervue, personal fees from Galimedix, grants, personal fees and
- non-financial support from Heidelberg Engineering, grants from Katairo, non-financial support
- from Optos, personal fees from Oxurion, outside the submitted work.
- 339 **Ramiro Ribeiro** is employed by Apellis Pharmaceuticals, Waltham, Massachusetts, USA.
- 340 **Reza Safaei** is employed by Apellis Pharmaceuticals, Waltham, Massachusetts, USA.
- 341 **Alex McKeown** is employed by Apellis Pharmaceuticals, Waltham, Massachusetts, USA.

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

|  | 342 | M. Fleckenstein re | ports grants, personal | fees and non-financial | support from Heidelberg |
|--|-----|--------------------|------------------------|------------------------|-------------------------|
|--|-----|--------------------|------------------------|------------------------|-------------------------|

- 343 Engineering, non-financial support from Zeiss Meditech, grants and non-financial support
- 344 from Optos, personal fees and grant from Novartis, personal fees from Bayer, grants and
- 345 personal fees from Genentech, from Roche, outside the submitted work; In addition, Dr.
- 346 Fleckenstein is an inventor on a patent US20140303013 A1 pending.
- 347 **F.G. Holz** reports personal fees from Acucela, Apellis, Bayer, Boehringer-Ingelheim,
- Bioeq/Formycon, Roche/Genentech, Geuder, Graybug, Gyroscope, Heidelberg Engineering,
- 349 IvericBio, Kanghong, LinBioscience, Novartis, Oxurion, Pixium Vision, Oxurion, Stealth
- BioTherapeutics, and Zeiss. Prof. Holz reports grants from Allergan, Apellis, Bayer,
- 351 Bioeq/Formycon, CenterVue, Ellex, Roche/Genentech, Geuder, Heidelberg Engineering,
- 352 IvericBio, Kanghong, NightStarX, Novartis, Optos, Pixium Vision, and Zeiss.
- 353 Role of Sponsor: The sponsor or funding organizations had no role in the conduct of the
- analysis but were involved in the interpretation of the data, preparation, review, and approval
- of the manuscript. The authors alone are responsible for the content and writing of the paper.
- 356 The views expressed are those of the authors.

#### 357 Data Sharing:

358 Original data will be shared from the corresponding authors upon reasonable request.

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 360 **REFERENCES**

- Fleckenstein, M. *et al.* Age-related macular degeneration. *Nat. Rev. Dis. Prim.* 7, 31 (2021).
- Schmitz-Valckenberg, S. *et al.* Geographic atrophy: Semantic considerations and
   literature review. *Retina* 36, 2250–2264 (2016).
- Holz, F. G., Strauss, E. C., Schmitz-Valckenberg, S. & Van Lookeren Campagne, M.
   Geographic atrophy: Clinical features and potential therapeutic approaches.
   *Ophthalmology* 121, 1079–1091 (2014).
- Hughes, S. *et al.* Prolonged intraocular residence and retinal tissue distribution of a
   fourth-generation compstatin-based C3 inhibitor in non-human primates. *Clin. Immunol.* 214, 108391 (2020).
- Liao, D. S. *et al.* Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy
   Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
   *Ophthalmology* 127, 186–195 (2020).
- Apellis Pharmaceuticals. Apellis Announces Top-Line Results from Phase 3 DERBY
   and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in
   the First Half of 2022.
- Fleckenstein, M. *et al.* The Progression of Geographic Atrophy Secondary to Age Related Macular Degeneration. *Ophthalmology* **125**, 369–390 (2018).
- Pfau, M. *et al.* Mesopic and Dark-Adapted Two-Color Fundus-Controlled Perimetry in
   Geographic Atrophy Secondary to Age-Related Macular Degeneration. *Retina* (2018).
   doi:10.1097/IAE.0000000002337
- Lindner, M. *et al.* Combined fundus autofluorescence and near infrared reflectance as
   prognostic biomarkers for visual acuity in foveal-sparing geographic atrophy. *Investig. Ophthalmol. Vis. Sci.* 58, BIO61–BIO67 (2017).
- Chakravarthy, U. *et al.* Characterizing Disease Burden and Progression of Geographic
   Atrophy Secondary to Age-Related Macular Degeneration. *Ophthalmology* **125**, 842–
   849 (2018).
- Sivaprasad, S. *et al.* Reliability and Construct Validity of the NEI VFQ-25 in a Subset
  of Patients With Geographic Atrophy From the Phase 2 Mahalo Study. *Am. J. Ophthalmol.* **190**, 1–8 (2018).
- Künzel, S. H. *et al.* Determinants of Quality of Life in Geographic Atrophy Secondary
   to Age-Related Macular Degeneration. *Invest. Ophthalmol. Vis. Sci.* 61, 63 (2020).
- Fleckenstein, M. *et al.* High-resolution spectral domain-OCT imaging in geographic
   atrophy associated with age-related macular degeneration. *Investig. Ophthalmol. Vis. Sci.* 49, 4137–4144 (2008).
- Li, M. *et al.* HISTOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE RELATED MACULAR DEGENERATION: A Multilayer Approach. *Retina* 38, 1937–
   1953 (2018).
- Spaide, R. F. Outer retinal atrophy after regression of subretinal drusenoid deposits as
  a newly recognized form of late age-related macular degeneration. *Retina* 33, 1800–
  1808 (2013).
- 402 16. Chen, L. *et al.* SUBRETINAL DRUSENOID DEPOSIT IN AGE-RELATED MACULAR
   403 DEGENERATION: Histologic Insights Into Initiation, Progression to Atrophy, and
   404 Imaging. *Retina* 40, 618–631 (2020).

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

17. 405 Steinberg, J. S. et al. Correlation of Partial Outer Retinal Thickness with Scotopic and 406 Mesopic Fundus-Controlled Perimetry in Patients with Reticular Drusen. Am. J. 407 Ophthalmol. 168, 52-61 (2016). 408 18. Gin, T. J., Wu, Z., Chew, S. K. H., Guymer, R. H. & Luu, C. D. Quantitative analysis of 409 the ellipsoid zone intensity in phenotypic variations of intermediate age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 58, 2079–2086 (2017). 410 411 19. Pfau, M. et al. Mesopic and dark-adapted two-color fundus-controlled perimetry in 412 patients with cuticular, reticular, and soft drusen. Eye **32**, 1819–1830 (2018). 413 20. Pfau, M. et al. Progression of Photoreceptor Degeneration in Geographic Atrophy 414 Secondary to Age-related Macular Degeneration. JAMA Ophthalmol. (2020). 415 doi:10.1001/jamaophthalmol.2020.2914 21. 416 Reiter, G. S. et al. Subretinal Drusenoid Deposits and Photoreceptor Loss Detecting 417 Global and Local Progression of Geographic Atrophy by SD-OCT Imaging. Invest. 418 Ophthalmol. Vis. Sci. 61, 11 (2020). 419 22. Bird, A. C., Phillips, R. L. & Hageman, G. S. Geographic atrophy: A histopathological 420 assessment. JAMA Ophthalmol. 132, 338-345 (2014). 421 23. Pfau, M. et al. Determinants of cone- and rod-function in geographic atrophy: Al-based 422 structure-function correlation. Am. J. Ophthalmol. 217, 162–173 (2020). 423 24. Riedl, S. et al. The effect of pegcetacoplan treatment on photoreceptor maintenance in 424 geographic atrophy monitored by Al-based OCT analysis. Ophthalmol. Retin. (2022). 425 doi:10.1016/j.oret.2022.05.030 Thiele, S. et al. Natural history of the relative ellipsoid zone reflectivity in age-related 426 25. 427 macular degeneration. Ophthalmol. Retin. (2022). doi:10.1016/j.oret.2022.06.001 26. 428 Schmitz-Valckenberg, S. et al. Fundus autofluorescence and fundus perimetry in the 429 junctional zone of geographic atrophy in patients with age-related macular 430 degeneration. Investig. Ophthalmol. Vis. Sci. 45, 4470–4476 (2004). 431 27. Künzel, S. H. et al. Association of Reading Performance in Geographic Atrophy 432 Secondary to Age-Related Macular Degeneration With Visual Function and Structural 433 Biomarkers. JAMA Ophthalmol. 139, 1191–1199 (2021). 434 28. Lindner, M. et al. Determinants of Reading Performance in Eyes with Foveal-Sparing 435 Geographic Atrophy. Ophthalmol. Retin. 3, 201–210 (2019). 436 29. Sunness, J. S. Reading newsprint but not headlines: pitfalls in measuring visual acuity 437 and color vision in patients with bullseve maculopathy and other macular scotomas. 438 Retin. Cases Brief Rep. 2, 83–84 (2008). 30. 439 Sunness, J. S. et al. The Long-term Natural History of Geographic Atrophy from Age-440 Related Macular Degeneration. Enlargement of Atrophy and Implications for 441 Interventional Clinical Trials. Ophthalmology 114, 271–277 (2007). 442 31. Pfau, M. et al. Green-Light Autofluorescence Versus Combined Blue-Light 443 Autofluorescence and Near-Infrared Reflectance Imaging in Geographic Atrophy 444 Secondary to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 58, 445 BIO121-BIO130 (2017). Holz, F. G. et al. Efficacy and safety of lampalizumab for geographic atrophy due to 446 32. 447 age-related macular degeneration: Chroma and spectri phase 3 randomized clinical 448 trials. JAMA Ophthalmol. 136, 666-677 (2018). 449 33. Schmitz-Valckenberg, S. et al. Semiautomated image processing method for 450 identification and quantification of geographic atrophy in age-related macular

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

451 degeneration. Investig. Ophthalmol. Vis. Sci. 52, 7640–7646 (2011).

- 452 34. Niu, S. *et al.* Automated retinal layers segmentation in SD-OCT images using dual453 gradient and spatial correlation smoothness constraint. *Comput. Biol. Med.* 54, 116–
  454 128 (2014).
- Gorgi Zadeh, S. *et al.* CNNs enable accurate and fast segmentation of drusen in
  optical coherence tomography. in *Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)*(eds. Cardoso, M. J. et al.) **10553 LNCS**, 65–73 (Springer International Publishing,
  2017).
- 460 36. Fang, L. *et al.* Automatic segmentation of nine retinal layer boundaries in OCT images
  461 of non-exudative AMD patients using deep learning and graph search. *Biomed. Opt.*462 *Express* 8, 2732 (2017).
- 463 37. Maloca, P. M. *et al.* Validation of automated artificial intelligence segmentation of optical coherence tomography images. *PLoS One* **14**, e0220063 (2019).
- 38. Zweifel, S. A., Spaide, R. F., Curcio, C. A., Malek, G. & Imamura, Y. Reticular
  Pseudodrusen Are Subretinal Drusenoid Deposits. *Ophthalmology* 117, 303–12.e1
  (2010).
- 468 39. Curcio, C. A. & Allen, K. A. Aging of the Human Photoreceptor Mosaic: Evidence for
  469 Selective Vulnerability of Rods in Central Retina. *Invest. Ophthalmol. Vis. Sci.* 34,
  470 3278–3296 (1993).
- 471 40. Curcio, C. A., Medeiros, N. E. & Millican, C. L. Photoreceptor loss in age-related 472 macular degeneration. *Investig. Ophthalmol. Vis. Sci.* **37**, 1236–1249 (1996).
- 473 41. Hill, A. B. The Environment and Disease: Association or Causation? *Proc. R. Soc.*474 *Med.* 58, 295–300 (1965).
- 475 42. Takahashi, A. *et al.* Photoreceptor Damage and Reduction of Retinal Sensitivity
  476 Surrounding Geographic Atrophy in Age-Related Macular Degeneration. *Am. J.*477 Ophthalmol. **168**, 260–268 (2016).
- 478 43. Pfau, M. *et al.* Light sensitivity within areas of geographic atrophy secondary to age-479 related macular degeneration. *Investig. Ophthalmol. Vis. Sci.* **60**, 3992–4001 (2019).
- 480 44. Pfau, M. *et al.* Mesopic And Dark-adapted Two-color Fundus-controlled Perimetry In
  481 Geographic Atrophy Secondary To Age-related Macular Degeneration. *Retina* 40,
  482 169–180 (2020).
- 483 45. Wu, Z. *et al.* Optical coherence tomography-defined changes preceding the
  484 development of drusen-associated atrophy in age-related macular degeneration.
  485 Ophthalmology 121, 2415–2422 (2014).
- 486 46. Wu, Z. *et al.* Prospective Longitudinal Evaluation of Nascent Geographic Atrophy in 487 Age-Related Macular Degeneration. *Ophthalmol. Retin.* **4**, 568–575 (2020).
- 488 47. Guymer, R. H. *et al.* Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy
  489 in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 4.
  490 Ophthalmology 127, 394–409 (2020).
- 491 48. Wu, Z. *et al.* OCT Signs of Early Atrophy in Age-Related Macular Degeneration:
  492 Interreader Agreement: Classification of Atrophy Meetings Report 6. *Ophthalmol.*493 *Retin.* 6, 4–14 (2022).
- 494
  49. Nittala, M. G. *et al.* Association of Pegcetacoplan With Progression of Incomplete
  495
  496 Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular
  496 Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial. *JAMA*

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 497 *Ophthalmol.* (2022). doi:10.1001/jamaophthalmol.2021.6067

- 50. Nittala, M. G. *et al.* Association of Pegcetacoplan With Progression of Incomplete
  Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular
  Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial. *JAMA Ophthalmol.* (2022). doi:10.1001/jamaophthalmol.2021.6067
- 502 51. Sadigh, S. *et al.* Abnormal thickening as well as thinning of the photoreceptor layer in intermediate age-related macular degeneration. *Investig. Ophthalmol. Vis. Sci.* 54, 1603–1612 (2013).
- 505 52. Lu, C. D. *et al.* Photoreceptor layer thickness changes during dark adaptation
  506 observed with ultrahigh-resolution optical coherence tomography. *Investig.*507 *Ophthalmol. Vis. Sci.* 58, 4632–4643 (2017).
- 508 53. Jaffe, G. J. *et al.* C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age509 Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
  510 *Ophthalmology* 128, 576–586 (2021).
- 511 54. Jaffe, G. J. *et al.* Development of IONIS-FB-LRx to treat geographic atrophy 512 associated with AMD. *Invest. Ophthalmol. Vis. Sci.* **61**, 4305 (2020).
- 513 55. Khanani, A. M. *et al.* Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment
  514 FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration.
  515 Am. J. Ophthalmol. 232, 49–57 (2021).
- 516 56. R Core Team. R: A Language and Environment for Statistical Computing. (2021).
- 517 57. Wickham, H., François, R., Henry, L. & Müller, K. dplyr: A Grammar of Data 518 Manipulation. (2021).
- 519 58. Valero-Mora, P. M. ggplot2: Elegant Graphics for Data Analysis . Journal of Statistical 520 Software **35**, (Springer, 2010).
- 521 59. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models 522 Using Ime4. *J. Stat. Software; Vol 1, Issue 1* (2015).
- 523 60. Lenth, R. V. emmeans: Estimated Marginal Means, aka Least-Squares Means. (2021).
- Martin Bland, J. & Altman, D. G. Statistical Methods for Assessing Agreement
   Between Two Methods of Clinical Measurement. *Lancet* 327, 307–310 (1986).

Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 526 FIGURES AND FIGURE LEGENDS

#### 527 Figure 1. Image segmentation approach

- 528 As shown in the first panel, all spectral-domain optical coherence tomography (SD-OCT)
- 529 data were segmented using a convolutional neural network (CNN, Deeplabv3 model with a
- 530 ResNet-50 backbone). Subsequently (second panel), these data were standardized (z-
- scores) to account for normal thickness variation due to age and retinal topography. Last
- 532 (third panel), the retinal layers' thicknesses were extracted along evenly spaced contour-lines
- surrounding the retinal pigment epithelium (RPE) atrophy area. The yellow line denotes the
- 534 boundary of RPE atrophy. The three purple lines represent the 0.43°, 2.58°, and 5.16°
- 535 contour-lines.
- 536 **Abbreviations:** spectral-domain optical coherence tomography (SD-OCT), convolutional
- 537 neural network (CNN), retinal pigment epithelium (RPE), outer nuclear layer (ONL),
- 538 photoreceptor inner segments (IS), photoreceptor outer segments (OS), retinal pigment
- 539 epithelium-drusen complex (RPEDC)



Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

### 542 Figure 2. Change in thickness at the level of the outer nuclear layer (ONL) over time

- 543 The plots show the average thickness at the level of the outer nuclear layer (ONL, y-axis)
- and the standard error of the mean (SEM, ribbons) with the distance to the boundary of
- retinal pigment epithelium (RPE) atrophy (x-axis). The panels indicate the visit, and the color
- 546 indicates the treatment arm. The vertical dashed lines denote the 0.43°, 2.58°, and 5.16°
- 547 contour-lines that were considered for the linear mixed model analyses. Please note that the
- 548 baseline junctional-zone ONL thickness differed slightly among the groups. The actual
- 549 contrasts (i.e., change-over-time from baseline) are shown in Figure 3.
- 550 The data were derived from the modified intention-to-treat (mITT) analysis (N<sub>participants</sub>= 192).
- 551 *Abbreviations:* outer nuclear layer (ONL), photoreceptor inner segments (IS), photoreceptor
- 552 outer segments (OS), modified intention-to-treat (mITT)



Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

#### 554 Figure 3. Change in thickness at the level of the photoreceptor layers along the 5.16°

#### 555 contour-line over time, modified intention-to-treat (mITT) analysis

- 556 The plots show the least-squares (adjusted) means from the linear mixed model analysis for
- 557 the change in thickness at the level of the outer nuclear layer (ONL), photoreceptor inner
- segments (IS), and photoreceptor outer segments (OS) along the 5.16° contour-line as a
- 559 function of the visit (x-axis) and treatment arm (colors). The vertical lines denote the 95%
- 560 confidence intervals. Eyes treated with pegcetacoplan (APL-2) monthly tended to show a
- 561 lesser degree of photoreceptor laminae thinning over time. Participants were treated
- 562 between baseline and month 12.
- 563 The data were derived from the modified intention-to-treat (mITT) analysis (N<sub>participants</sub>= 192).
- 564 **Abbreviations:** outer nuclear layer (ONL), photoreceptor inner segments (IS), photoreceptor
- 565 outer segments (OS), modified intention-to-treat (mITT)



Pfau et al. Association of pegcetacoplan therapy with photoreceptor degeneration

# 567 TABLES

# 568 Table 1. Cohort characteristics for the included participants (modified intention-to-

# 569 treat [mITT] with Spectralis imaging)

### 570 **Abbreviations:** retinal pigment epithelium (RPE), square-root (SQRT)

571

|  | Sham pooled<br>(N=64) | APL-2 Monthly<br>(N=67) | APL-2 EOM<br>(N=61) | P-value for the<br>between group<br>difference* |  |
|--|-----------------------|-------------------------|---------------------|---|--|
| Age in years   |                       |                         |                     |   |  |
| Mean (SD)  | 78.0 (7.62)           | 80.1 (7.44)             | 80.3 (7.43)         | 0.16  |  |
| Median [Min, Max]  | 78.0 [60.0, 96.0]     | 81.0 [63.0, 95.0]       | 80.0 [60.0, 97.0]   | 0.10  |  |
| Sex  |                       |                         |                     |   |  |
| F  | 38 (59.4%)            | 44 (65.7%)              | 40 (65.6%)          | 0.74  |  |
| М  | 26 (40.6%)            | 23 (34.3%)              | 21 (34.4%)          | 0.71  |  |
| Laterality   |                       |                         |                     |   |  |
| L  | 31 (48.4%)            | 27 (40.3%)              | 20 (32.8%)          | 0.04  |  |
| R  | 33 (51.6%)            | 40 (59.7%)              | 41 (67.2%)          | 0.21  |  |
| Study eye SQRT-<br>transformed area of RPE-<br>atrophy in mm |                       |                         |                     |   |  |
| Mean (SD)  | 2.78 (0.725)          | 2.75 (0.663)            | 2.88 (0.772)        | 0.60  |  |
| Median [Min, Max]  | 2.65 [1.60, 4.07]     | 2.74 [1.59, 4.16]       | 3.00 [1.59, 4.12]   | 0.00  |  |

\* Between-group differences in continuous variables (age and sqrt. area of atrophy) were evaluated with an

573 ANOVA, and Fisher's exact test was applied for categorical data (sex and laterality).

|       |                               |          |               |          | 2 5 Qº   |                |          | 5 16°    | 5 16°         |          |
|-------|-------------------------------|----------|---------------|----------|----------|----------------|----------|----------|---------------|----------|
| Layer | Contrast                      | Estimate | 95% Cl        | P-value* | Estimate | 95% Cl         | P-value* | Estimate | 95% Cl        | P-value* |
| ONL   | (APL-2 Monthly) - Sham pooled | 0.1      | [-0.03, 0.24] | .16      | 0.26     | [0.14, 0.38]   | <.001    | 0.29     | [0.16, 0.42]  | <.001    |
| ONL   | (APL-2 EOM) - Sham pooled     | 0.12     | [-0.01, 0.26] | .09      | 0.16     | [0.04, 0.29]   | .006     | 0.26     | [0.13, 0.4]   | <.001    |
| ONL   | (APL-2 Monthly) - (APL-2 EOM) | -0.02    | [-0.15, 0.12] | .95      | 0.09     | [-0.03, 0.22]  | .17      | 0.02     | [-0.11, 0.16] | .92      |
| IS    | (APL-2 Monthly) - Sham pooled | 0.68     | [0.09, 1.28]  | .02      | 0.48     | [0.21, 0.75]   | <.001    | 0.42     | [0.21, 0.62]  | <.001    |
| IS    | (APL-2 EOM) - Sham pooled     | 1.09     | [0.48, 1.71]  | <.001    | 0.4      | [0.12, 0.68]   | .002     | 0.34     | [0.12, 0.55]  | <.001    |
| IS    | (APL-2 Monthly) - (APL-2 EOM) | -0.41    | [-1.02, 0.2]  | .26      | 0.08     | [-0.2, 0.36]   | .78      | 0.08     | [-0.13, 0.29] | .64      |
| OS    | (APL-2 Monthly) - Sham pooled | -0.09    | [-0.38, 0.19] | .72      | 0.18     | [-0.12, 0.48]  | .33      | 0.29     | [-0.01, 0.58] | .06      |
| OS    | (APL-2 EOM) - Sham pooled     | 0.05     | [-0.24, 0.35] | .9       | 0.52     | [0.21, 0.83]   | <.001    | 0.3      | [-0.01, 0.6]  | .06      |
| OS    | (APL-2 Monthly) - (APL-2 EOM) | -0.15    | [-0.44, 0.14] | .45      | -0.34    | [-0.64, -0.03] | .03      | -0.01    | [-0.31, 0.3]  | 1        |

#### Table 2. Study eye differences in thickness at the level of photoreceptor layers (in z-score units) at three contour-lines at month 12 574

(modified intention-to-treat [mITT] analysis) 575

576

\* P-values were obtained using Kenward-Roger approximation to estimate the denominator degrees of freedom. P-values were adjusted within 577

each model (i.e., combination of layer and contour-line) using the Tukey method for comparing a family of 3 estimates. 578